253 related articles for article (PubMed ID: 18468523)
1. Combating counterfeit drugs.
Lancet; 2008 May; 371(9624):1551. PubMed ID: 18468523
[No Abstract] [Full Text] [Related]
2. World agencies try to stem flood of fake drugs.
Surendran A
Nat Med; 2004 Feb; 10(2):111. PubMed ID: 14760401
[No Abstract] [Full Text] [Related]
3. [Contaminated heparins].
Monneret C
Ann Pharm Fr; 2008 Aug; 66(4):212-5. PubMed ID: 18847567
[TBL] [Abstract][Full Text] [Related]
4. Protecting consumers from counterfeit drugs.
FDA Consum; 2004; 38(3):12-3. PubMed ID: 15218838
[No Abstract] [Full Text] [Related]
5. [Illegal drug trade discovered in Bavaria. How can we protect ourselves from drug falsification?].
Schweim HG
MMW Fortschr Med; 2005 Sep; 147(38):11. PubMed ID: 16218221
[No Abstract] [Full Text] [Related]
6. Report on the PQRI impurity characterization and quantification best practices survey.
Faustino P; Chan CC; Carrano J; Gosnell M; Gu ZQ; Maule A; Sigvardson K; Zhang YF
Pharm Res; 2006 Feb; 23(2):440-6. PubMed ID: 16477396
[No Abstract] [Full Text] [Related]
7. As production goes global, drug supply faces greater risks to safety, quality.
Kuehn BM
JAMA; 2011 Aug; 306(8):811-3. PubMed ID: 21862736
[No Abstract] [Full Text] [Related]
8. Standardization of forensic drug analyses.
Frank RS; Gunn JW
J Forensic Sci; 1974 Jan; 19(1):163-7. PubMed ID: 4854386
[No Abstract] [Full Text] [Related]
9. Combating counterfeit drugs.
Land T
Nature; 1992 Jan; 355(6357):192. PubMed ID: 1731208
[No Abstract] [Full Text] [Related]
10. Regulators scramble to tighten loopholes after heparin debacle.
Jia H
Nat Biotechnol; 2008 May; 26(5):477-8. PubMed ID: 18464756
[No Abstract] [Full Text] [Related]
11. Adulteration of drugs and foods: compendial approaches to lowering risk.
Abernethy DR; Sheehan C; Griffiths JC; Williams RL;
Clin Pharmacol Ther; 2009 Apr; 85(4):444-7. PubMed ID: 18463621
[No Abstract] [Full Text] [Related]
12. Aseptic process monitoring--a better strategy. Validation Group, Inc.
Wilson JD
PDA J Pharm Sci Technol; 1999; 53(3):111-4. PubMed ID: 10754699
[No Abstract] [Full Text] [Related]
13. Pharmaceutical drugs-the good and the not so good: together, we can make it better.
Campbell AW
Altern Ther Health Med; 2014; 20(1):9-11. PubMed ID: 24445351
[No Abstract] [Full Text] [Related]
14. Deterring the importation of counterfeit pharmaceutical products.
Stearn DW
Food Drug Law J; 2004; 59(4):537-61. PubMed ID: 15875351
[No Abstract] [Full Text] [Related]
15. Toward more effective drug regulation.
Schmidt AM
FDA Consum; 1975 Dec-1976 Jan; 9(10):27-9. PubMed ID: 10316532
[No Abstract] [Full Text] [Related]
16. Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products.
Fed Regist; 1978 Sep; 43(190 Pt 2):45013-89. PubMed ID: 10316700
[No Abstract] [Full Text] [Related]
17. Industry perspective on the medical risk of visible particles in injectable drug products.
Bukofzer S; Ayres J; Chavez A; Devera M; Miller J; Ross D; Shabushnig J; Vargo S; Watson H; Watson R
PDA J Pharm Sci Technol; 2015; 69(1):123-39. PubMed ID: 25691720
[No Abstract] [Full Text] [Related]
18. Substandard medicines in resource-poor settings: a problem that can no longer be ignored.
Caudron JM; Ford N; Henkens M; Macé C; Kiddle-Monroe R; Pinel J
Trop Med Int Health; 2008 Aug; 13(8):1062-72. PubMed ID: 18631318
[TBL] [Abstract][Full Text] [Related]
19. Moulds associated with contaminated ocular and injectable drugs: FDA recalls, epidemiology considerations, drug shortages, and aseptic processing.
Ahearn DG; Stulting RD
Med Mycol; 2018 Jun; 56(4):389-394. PubMed ID: 29420758
[TBL] [Abstract][Full Text] [Related]
20. Impact of poor-quality medicines in the 'developing' world.
Newton PN; Green MD; Fernández FM
Trends Pharmacol Sci; 2010 Mar; 31(3):99-101. PubMed ID: 20117849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
